Posted by Michael Wonder on 22 Mar 2023
FDA approves first in class Evkeeza (evinacumab-dgnb) for young children with ultra rare form of high cholesterol
22 March 2023 - Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolaemia, an inherited condition characterised by extremely high low density lipoprotein cholesterol.
Regeneron Pharmaceuticals today announced the US FDA has extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolaemia.
